<DOC>
	<DOCNO>NCT01664728</DOCNO>
	<brief_summary>The purpose study provide access abiraterone acetate patient complete 12 cycle abiraterone acetate treatment Clinical Study COU-AA-001 continue receive clinical benefit treatment .</brief_summary>
	<brief_title>An Expanded Access Study Abiraterone Acetate Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001</brief_title>
	<detailed_description>This open-label ( identity study drug know ) extend access study evaluate safety efficacy continue administration abiraterone acetate patient complete 12 cycle abiraterone acetate treatment Clinical Study COU-AA-001 continue receive clinical benefit treatment . Patients continue dose regimen administer end Study COU-AA-001 receive low-dose glucocorticoid daily . Patients follow every 3 month disease progression survival 3 year follow study entry . Safety monitor throughout study 30 day last dose study medication .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Completed 12 cycle abiraterone acetate study COUAA001 Last dose abiraterone acetate within 14 day prior treatment study Demonstrates potential gain clinical benefit continue abiraterone acetate treatment Serum potassium level &gt; =3.5 mmol/L Eastern Cooperative Oncology Group Performance Status &lt; 3 ( Karnofsky Performance Status &gt; =30 % ) Agrees protocoldefined use effective contraception Serious uncontrolled coexistent nonmalignant disease , include active uncontrolled infection Uncontrolled hypertension Abnormal liver function Clinically significant heart disease evidence myocardial infarction past 12 month , severe unstable angina , New York Heart Association ( NYHA ) Class III IV heart disease ( patient history atherosclerotic vascular disease require coronary peripheral artery bypass surgery may enrol provide surgery occur least 2 year prior enrollment consultation cardiologist insure disease stable ) Condition situation , investigator 's opinion , may put patient significant risk , may confound study result , may interfere significantly patient 's participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Prostate neoplasm</keyword>
	<keyword>Hormone refractory prostate cancer</keyword>
	<keyword>Castration resistant prostate cancer</keyword>
	<keyword>Castration refractory prostate cancer</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>CB7630</keyword>
</DOC>